GLP-1 Receptor Agonists: A Comparative Overview

Background

GLP-1 receptor agonists emerged from incretin biology — the observation that orally delivered glucose produces a greater insulin response than the same glucose delivered intravenously. The peptides responsible for this effect, GLP-1 and GIP, became targets for analogs designed to resist enzymatic degradation and extend half-life.

The first clinically successful long-acting GLP-1 analogs reshaped diabetes care and, more recently, the treatment of obesity. The current generation extends activity to multiple incretin receptors simultaneously.

Semaglutide

A GLP-1 receptor agonist with structural modifications (Aib substitution at position 8 and a C-18 fatty diacid side chain) that confer DPP-4 resistance and albumin binding. Half-life is approximately one week in research models, supporting weekly dosing schedules in published literature.

Tirzepatide

A dual GIP/GLP-1 receptor agonist. The simultaneous activation of both incretin pathways produces effects on glycemia and body weight in research models that exceed selective GLP-1 agonism in published comparisons. Half-life is similar to semaglutide.

Retatrutide

A triple agonist active at GLP-1, GIP, and glucagon receptors. The glucagon component adds an energy-expenditure dimension to the incretin profile. Phase 2 clinical data in obesity research has drawn significant attention.

Cagrilintide

A long-acting amylin analog. Frequently studied in combination with semaglutide (the CagriSema combination) for additive effects on satiety and glycemia in research settings.

Considerations

When evaluating these compounds as reference material, key documentation includes HPLC purity, mass-spectrometric identity confirmation, water content, and acetate counter-ion content. These specifications appear on every lot-specific COA.